Explore | Popular

2 investments found

Single Technologies

SINGLE has developed the world’s fastest DNA sequencing technology at the lowest known cost in the market. This current offering will finalize product development and market entry.
Funded SEK 14,999,030.20
Target SEK 6,999,986
Capital Target SEK 14,999,970
Min. Raise SEK 6,999,986
Percent of Equity Offered 15%
Valuation of equity SEK 100000000
End Date 15 May 2019
1 Startup Stockholm
View Investment

Athera Biotechnologies

Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological drugs for treatment of cardiovascular disease.
Funded SEK 55,095,000
Target SEK 30,000,000
Capital Target SEK 60,000,000
Min. Raise SEK 30,000,000
Percent of Equity Offered 55%
Valuation of equity SEK 110000000
End Date 21 April 2019
2 Growth
View Investment